A synergistic blend of four traditional Chinese medicinal herbs—Astragalus membranaceus, Salvia miltiorrhiza, Panax notoginseng, and Dalbergia odorifera—has demonstrated significant potential in modern cardiology, building on centuries of use in traditional medicine. Astragalus membranaceus is widely valued for its potent anti-inflammatory and adaptogenic effects, helping the body manage stress and inflammation. Salvia miltiorrhiza, known for its "blood-activating" properties, supports cardiovascular health while also providing antiviral, antimicrobial, anti-cancer, and anti-inflammatory benefits. Panax notoginseng complements these actions with its strong anti-inflammatory, anti-cancer, and anticoagulant properties, while Dalbergia odorifera has been traditionally used to treat cardio-cerebrovascular conditions, enhancing overall heart and blood vessel function.
In this review, we examine the collective therapeutic potential of these herbs through clinical evaluations conducted by Tasly (Malaysia) Sdn. Bhd., a leading name in herbal medicine research. The study focuses on their cardioprotective effects, analyzing key blood inflammation markers such as IL-6, IL-10, TNF-α, IFN-γ, CK-BB, CK-MM, and the IL-6/IL-10 ratio. These markers are critical indicators of inflammation and immune response, particularly in cardiovascular diseases. Furthermore, changes in gut microbiota, a crucial factor influencing systemic inflammation and overall health, were assessed before and after a one-month treatment period.
The results highlight the herbs' ability to modulate inflammatory responses, improve cardiovascular health, and restore gut microbiome balance. Such findings underline their potential not only as a complementary therapy but also as a bridge between traditional remedies and modern medicine. This comprehensive evaluation demonstrates that the combination of these herbs could offer a natural, effective solution for managing cardiovascular diseases, paving the way for their wider clinical application.